MedPath

Fpllow-up study of multicenter, prospective, randomised and comparative study of alternative anti-androgen (AA) therapy and early initiating enzalutamide for castration-resistant prostate cancer (CRPC) after combined androgen blockade (CAB) therapy with bicalutamide (OCUU-CRPC follow-up study).

Not Applicable
Conditions
Castration-resistant prostate cancer
Registration Number
JPRN-UMIN000039155
Lead Sponsor
Department of Urology, Osaka City University Graduate School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
Male
Target Recruitment
103
Inclusion Criteria

Not provided

Exclusion Criteria

None

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
overall survival (OS)
Secondary Outcome Measures
NameTimeMethod
time to treatment failure of ENZA therapy (TTF-ENZA)
© Copyright 2025. All Rights Reserved by MedPath